Screening and management of metabolic complications of mTOR inhibitors in real-life settings.
Fiche publication
Date publication
décembre 2023
Journal
Annales d'endocrinologie
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PETIT Jean-Michel, Pr VERGES Bruno, Pr SCHMITT Antonin
Tous les auteurs :
Spanjaard P, Petit JM, Schmitt A, Vergès B, Bouillet B
Lien Pubmed
Résumé
Inhibitors of mTOR (mTORi) are frequently used as anticancer treatment. They were responsible for metabolic side-effects in phase 3 studies, which provided only an incomplete picture of these metabolic complications. The aim of our study was therefore to evaluate, in a real-life setting, outcomes for patients with dyslipidemia or diabetes under mTORi, and the incidence and management of metabolic abnormalities occurring under mTORi in the absence of known metabolic history.
Mots clés
diabetes, dyslipidemia, mTOR inhibitors, metabolic complications
Référence
Ann Endocrinol (Paris). 2023 12 1;: